CD44 and glioblastoma: The use of GK921, an inhibitor that specifically blocks TG2’s catalytic activity, reduced CD44 and master transcription factor expression levels which in turn blocked cell growth in MES subtype cells and tumor formation in an GBM orthotopic xenograft mouse model [56].